Senti Biosciences Holdings (SNTI) Financial Statements & Analysis

Senti Biosciences Holdings (SNTI) Income Statement

Senti Biosciences Holdings reported revenue of $22.00K in fiscal 2025 (fiscal year ended Dec 31, 2025). Senti Biosciences Holdings posted a net loss of $61.44M, compared with a net loss of $52.79M a year earlier. Gross margin was 100.0% and operating margin -312631.8%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $17.00K.

Senti Biosciences Holdings Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Senti Biosciences Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	0.02	0.00	1.98	3.29	2.29	0.57	0.09
Cost of Revenue	37.59	0.00	0.00	0.00	21.96	15.96	14.52
Gross Profit	0.02	0.00	1.98	3.29	2.76	-15.39	-14.44
Operating Expenses
Research & Development	37.59	34.36	32.15	28.15	21.96	15.96	14.52
Selling, General & Administrative	20.74	23.51	34.87	37.63	21.25	9.30	7.34
Operating Expenses	68.80	60.73	94.71	65.37	42.74	9.30	7.39
Operating Income	-68.78	-60.73	-92.73	-62.08	-40.45	-24.69	-21.78
Other Income/Expense
Interest Income	0.93	0.95	2.86	1.70	0.01	0.09	0.67
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	7.34	6.99	9.32	10.72	-14.88	-0.05	0.63
Income
Income Before Tax	-61.44	-52.79	-83.41	-49.67	-55.32	-19.86	-21.16
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-61.44	-52.79	-71.06	-58.21	-55.32	-19.86	-21.16
Net Income - Continuous Operations	-61.44	-52.79	-71.06	-49.67	-55.32	-19.86	-21.16
Net Income - Discontinued Operations	-	-	12.35	-8.55	-	-	-
EBITDA	-54.67	-56.89	-61.34	-58.16	-37.44	-24.13	-21.36
EBIT	-58.30	-60.73	-66.77	-62.08	-40.45	-24.69	-
Depreciation & Amortization	3.64	2.86	5.43	0.59	3.01	0.56	0.43
Earnings Per Share
Basic EPS	-3.00	-12.00	-21.00	-22.00	-13.00	-14.00	-16.00
Diluted EPS	-3.00	-12.00	-21.00	-22.00	-13.00	-14.00	-16.00
Basic Shares Outstanding	22.48	4.60	4.44	2.61	4.37	1.39	1.36
Diluted Shares Outstanding	22.48	4.60	4.44	2.61	4.37	1.39	1.36

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Senti Biosciences Holdings Financial Statements

What was Senti Biosciences Holdings's revenue in fiscal 2025?

Senti Biosciences Holdings reported revenue of $22.00K in fiscal 2025 (fiscal year ended Dec 31, 2025).

Is Senti Biosciences Holdings profitable?

No. Senti Biosciences Holdings reported a net loss of $61.44M in fiscal 2025. In fiscal 2024 it lost $52.79M.

What is Senti Biosciences Holdings's operating margin?

Senti Biosciences Holdings's operating income was −$68.78M on revenue of $22.00K in fiscal 2025, an operating margin of -312631.8%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition